CIK 2010850
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 97.48% | 12 |
| Unclassified | 2.52% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | CGON | CG Oncology, Inc. | Health Care | 65.21% |
| 2 | NUVB | Nuvation Bio Inc. | Health Care | 16.84% |
| 3 | UPB | Upstream Bio, Inc. | Health Care | 3.71% |
| 4 | ACRS | Aclaris Therapeutics, Inc. | Health Care | 2.29% |
| 5 | AARD | Aardvark Therapeutics, Inc. | Health Care | 2.23% |
| 6 | LYEL | Lyell Immunopharma, Inc. | Health Care | 2.10% |
| 7 | NAMS | NEWAMSTERDAM PHARMA COMPANY | Unclassified | 1.57% |
| 8 | RCUS | Arcus Biosciences, Inc. | Health Care | 1.56% |
| 9 | RVMD | Revolution Medicines, Inc. | Health Care | 1.37% |
| 10 | EQ | Equillium, Inc. | Health Care | 1.34% |
12/14 names classified · sector 97.5% of weight · industry 97.5% · mkt cap 97.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 97.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/14 names) · unclassified 100.0%: CGON, NUVB, UPB, ACRS, AARD, LYEL, NAMS, RCUS, RVMD, EQ +4 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | CGONCG ONCOLOGY INC | 6,371,669 | $431M | 65.2% | HOLD |
| 2 | NUVBNUVATION BIO INC | 25,954,439 | $111M | 16.8% | HOLD |
| 3 | UPBUPSTREAM BIO INC | 2,724,868 | $25M | 3.7% | TRIM −13% |
| 4 | ACRSACLARIS THERAPEUTICS INC | 4,041,736 | $15M | 2.3% | HOLD |
| 5 | AARDAARDVARK THERAPEUTICS INC | 3,917,299 | $15M | 2.2% | HOLD |
| 6 | LYELLyell Immunopharma, Inc. | 692,050 | $14M | 2.1% | HOLD |
| 7 | NAMSNEWAMSTERDAM PHARMA COMPANY | 325,057 | $10M | 1.6% | TRIM −45% |
| 8 | RCUSARCUS BIOSCIENCES INC | 477,819 | $10M | 1.6% | TRIM −12% |
| 9 | RVMDREVOLUTION MEDICINES INC | 93,500 | $9M | 1.4% | TRIM −53% |
| 10 | EQEQUILLIUM INC | 4,447,308 | $9M | 1.3% | HOLD |
| 11 | BYSIBEYONDSPRING INC | 3,800,702 | $6M | 0.9% | HOLD |
| 12 | ZNTLZENTALIS PHARMACEUTICALS INC | 1,323,327 | $3M | 0.5% | HOLD |
| 13 | KRYSKRYSTAL BIOTECH INC | 7,300 | $2M | 0.3% | TRIM −58% |
| 14 | PYXSPYXIS ONCOLOGY INC | 326,810 | $477,143 | 0.1% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| CGONCG ONCOLOGY INC | 6.4M | 6.4M | 6.4M | 6.4M | 6.4M | 6.4M | $431M |
| NUVBNUVATION BIO INC | 26.0M | 26.0M | 26.0M | 26.0M | 26.0M | 26.0M | $111M |
| UPBUPSTREAM BIO INC | 3.3M | 3.3M | 3.3M | 3.3M | 3.1M | 2.7M | $25M |
| ACRSACLARIS THERAPEUTICS INC | 2.3M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | $15M |
| AARDAARDVARK THERAPEUTICS INC | — | 3.9M | 3.9M | 3.9M | 3.9M | 3.9M | $15M |
| LYELLyell Immunopharma, Inc. | 11.9M | 11.9M | 595K | 595K | 692K | 692K | $14M |
| NAMSNEWAMSTERDAM PHARMA COMPANY | 770K | 770K | 770K | 657K | 592K | 325K | $10M |
| RCUSARCUS BIOSCIENCES INC | 809K | 809K | 160K | 548K | 542K | 478K | $10M |
| RVMDREVOLUTION MEDICINES INC | 226K | 226K | 226K | 210K | 200K | 94K | $9M |
| EQEQUILLIUM INC | 4.4M | 4.4M | 4.4M | 4.4M | 4.4M | 4.4M | $9M |
| BYSIBEYONDSPRING INC | 4.9M | 4.9M | 4.5M | 4.3M | 3.8M | 3.8M | $6M |
| ZNTLZENTALIS PHARMACEUTICALS INC | 2.3M | 2.0M | 1.3M | 1.3M | 1.3M | 1.3M | $3M |
| KRYSKRYSTAL BIOTECH INC | 77K | 65K | 66K | 32K | 17K | 7K | $2M |
| PYXSPYXIS ONCOLOGY INC | 327K | 327K | 327K | 327K | 327K | 327K | $477,143 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
